HOPKINTON, Mass., April 13, 2020 (Newswire.com) - Isto Biologics, a leading orthobiologics company focused on helping patients heal faster, has just been named a 2020 Top 10 Orthopedic Solution Provider by MedTech Outlook for exhibiting innovative technologies and strategies that can effectively and economically address the major challenges in orthopedics.
Isto Biologics is committed to improving patient quality of life by using the science of human biology to advance solutions for spine, orthopedics, regenerative medicine, and sports medicine. With a dedication to helping patients heal faster, this acknowledgement with MedTech Outlook further validates Isto Biologics’ core mission of providing patients with the highest level of care necessary.
The company works closely with orthopedic spine, trauma, joint, and foot and ankle surgeons to understand their unique needs and offer a robust portfolio of solutions for bone regeneration and cell-based therapies. Among Isto Biologics’ broadening portfolio, their best-in-class solutions include the Magellan®Autologous Concentration System; InQu®, a cell-friendly biosynthetic bone graft extender and substitute; and Influx™, a line of advanced allograft technology.
The latest innovation from Isto Biologics is InfluxTM SPARC, a next-generation, Cellular Bone Matrix (CBM) containing essential components for new bone development. This fully pliable, cellular-enriched allograft has a high concentration of growth factors for use in bone repair or reconstruction.
InfluxTM SPARC is an addition to Isto Biologics’ existing InfluxTM portfolio, a line of advanced allograft technology that delivers regenerative capacity in a versatile, 100% pure human bone graft.
“We are honored to be named a 2020 Top Provider of Orthopedic Solutions,” said Don Brown, Isto Biologics chief executive officer. “As pioneers in the orthobiologics space, we will always be committed to providing novel solutions for our surgeons and their patients and will continue to make advancements to fill the gaps in the industry.”
To learn more about how Isto Biologics is pioneering the use of biologic solutions to enable rapid bone healing, visit their MedTech Outlook profile here.
About Isto Biologics
Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, MA, merged under the Isto Holdings umbrella. Isto Biologics is focused on Helping Patients Heal FasterTM through innovative solutions for bone regeneration and cell-based therapies. The company’s flagship product offerings include the market-leading Magellan® autologous platelet separator and bone-growth products including InQu® Bone Graft Extender & Substitute, and Influx™, a line of natural bone graft material.
For more information or to learn more, view our solutions.
Source: Isto Biologics